Ceftolozane/tazobactam vs meropenem for febrile neutropenia with ESBL risk
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a fever and a low white blood cell count (febrile neutropenia).
- You are either colonized with a resistant bacteria called ESBL, or you've taken certain strong antibiotics (like cephalosporins or piperacillin/tazobactam) for at least 2 days in the last month.
- You have not been found to carry bacteria that are resistant to the study drugs (carbapenems or ceftolozane/tazobactam).
- You have not used carbapenem antibiotics (like meropenem) for at least 2 days in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial tests whether the antibiotic cefotetan works as well as current standard treatments for E. coli bloodstream infections that start in the urinary tract. If you qualify, you may receive either cefotetan or the usual antibiotic therapy.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial tests a combination of two antibiotics (cefepime and enmetazobactam) to treat complicated urinary tract infections that have spread to the blood. It aims to see if this new combination works better than other antibiotics and is safe for patients.
This trial compares two antibiotics, ciprofloxacin and ceftazidime, to see which works better for treating fever in children with blood cancer who have a high risk of infection due to low white blood cells. The goal is to find the best treatment to help your child recover faster.
Hear when a new Febrile Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.